跳至主要内容
临床试验/IRCT20150303021315N8
IRCT20150303021315N8招募中2 期

Comparison of the the efficacy and safety of Eculizumab (produced by CinnaGen) with placebo in patients with Paroxysmal Nocturnal Haemoglobinuria

CinnaGen Company0 个研究点目标入组 28 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
入组人数
28

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 no limit(—)
性别
All

入选标准

  • Patients 18 years of age or older
  • who had received at least four transfusions during the previous 12 months
  • Platelet counts of at least 100,000 per cubic millimeter
  • Lactate dehydrogenase levels that were at least 1.5 times the upper limit of the normal range
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 1 or less
  • PNH(Paroxysmal Nocturnal Haemoglobinuria) diagnosis after flow cytometry and assessment of CD55 and CD59;

排除标准

  • Mean hemoglobin level greater than 10.5 g per deciliter before transfusion during the 12 months before entry into the study
  • Receiving another investigational drug within 30 days before the first visit
  • Patients who had a complement deficiency
  • Active bacterial infection
  • History of meningococcal disease
  • Those who had undergone bone marrow transplantation
  • Pregnant and nursing women

研究者

相似试验